Vaccinex, Inc. (VCNX), a clinical-stage biotechnology firm, reported financial results for the full year 2025, reflecting a narrower net loss.
Company Details
Vaccinex engages in the discovery and development of targeted biotherapeutics for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.
Its lead candidate, Pepinemab, is being developed for Alzheimer's and Huntington's disease and is also under evaluation in other oncology settings.
2025 Results
For the full year 2025, net loss attributable to Vaccinex shareholders shrank to $5.26 million, or $1.97 per share, from $18.63 million, or $8.88 per share, in the prior year.
Collaboration and research-based revenue increased to $2.09 million from $0.60 million in the prior year.
Cash and cash equivalents at the end of the period totalled $0.140 million.
VCNX has traded between $0.31 and $1.50 over the last year. The stock closed Wednesday's trade at $0.78, down 14.29%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.